

# Corporate Action Notice

April 11, 2016

## Cash Distribution Resulting from the Sale of Shares

### BioGaia AB

**DR CUSIP:** 09072J102 / **ISIN:** US09072J1025

**DR Ticker Symbol:** BIOGY

**Ratio:** (DR: Underlying Share): 2:1

BioGaia AB announced a distribution of Infant Bacterial Therapeutics Shares to its Ordinary shareholders. The Shares were allocated as follows: 1 Infant Bacterial Therapeutics Share(s) were issued for every 10 Ordinary share(s) held as of the local record date of Mar 23, 2016.

The Infant Bacterial Therapeutics Shares were not registered under the United States Securities Act of 1933, therefore we were not permitted to pass the Shares on to the holders of Depositary Receipts ("DRs"). As a result, BNY Mellon has sold the Shares in the local market and the proceeds received from the sale will be distributed to the DR holders of BioGaia.

**BNY MELLON HAS ESTABLISHED  
THE FOLLOWING DATES FOR THIS  
CORPORATE ACTION:**

<b>DR Record Date:</b>	<b>April 22, 2016</b>
<b>DR Payment Date:</b>	<b>April 29, 2016</b>
<b>Gross Rate per DS:</b>	<b>\$0.662950</b>
<b>Depository Fee per DS:</b>	<b>(\$0.050000)</b>
<b>Net Rate per DS:</b>	<b>\$0.612950</b>

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

#### NEW YORK

Ravi Davis  
Richard J Maehr  
+ 1 212 815 2267  
adrdesk@bnymellon.com

#### LONDON

Jacek Jankowski  
Vice President  
+ 44 207 163 7427  
jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at [https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset\\_upload\\_file703\\_197380.pdf](https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file703_197380.pdf). Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.



**BNY MELLON**